- Home
- SYRE vs BEATW Comparison
SYRE vs BEATW Comparison
Compare SYRE & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- BEATW
- Stock Information
- Founded
- SYRE 2013
- BEATW N/A
- Country
- SYRE United States
- BEATW United States
- Employees
- SYRE N/A
- BEATW 20
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- BEATW Retail: Computer Software & Peripheral Equipment
- Sector
- SYRE Health Care
- BEATW Technology
- Exchange
- SYRE Nasdaq
- BEATW Nasdaq
- Market Cap
- SYRE N/A
- BEATW N/A
- IPO Year
- SYRE 2016
- BEATW 2021
- Fundamental
- Price
- SYRE $20.62
- BEATW $0.57
- Analyst Decision
- SYRE Strong Buy
- BEATW
- Analyst Count
- SYRE 8
- BEATW 0
- Target Price
- SYRE $51.50
- BEATW N/A
- AVG Volume (30 Days)
- SYRE 538.5K
- BEATW N/A
- Earning Date
- SYRE 02-27-2025
- BEATW N/A
- Dividend Yield
- SYRE N/A
- BEATW N/A
- EPS Growth
- SYRE N/A
- BEATW N/A
- EPS
- SYRE N/A
- BEATW N/A
- Revenue
- SYRE N/A
- BEATW N/A
- Revenue This Year
- SYRE $168.62
- BEATW N/A
- Revenue Next Year
- SYRE $47.61
- BEATW N/A
- P/E Ratio
- SYRE N/A
- BEATW N/A
- Revenue Growth
- SYRE N/A
- BEATW N/A
- 52 Week Low
- SYRE $20.07
- BEATW N/A
- 52 Week High
- SYRE $47.97
- BEATW N/A
- Technical
- Relative Strength Index (RSI)
- SYRE 32.81
- BEATW N/A
- Support Level
- SYRE $20.36
- BEATW N/A
- Resistance Level
- SYRE $22.49
- BEATW N/A
- Average True Range (ATR)
- SYRE 1.43
- BEATW 0.00
- MACD
- SYRE -0.11
- BEATW 0.00
- Stochastic Oscillator
- SYRE 5.11
- BEATW 0.00
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.